anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To characterize molecular markers for risk of adult T-cell leukemia/lymphoma (ATL), whose incidence rate differs greatly across geographic areas, we propose to examine the prevalence and level of viral and host immune response markers as well as the protein expression pattern of 57 subjects who subsequently developed ATL and 171 matched control subjects who participated in various prospective studies of carriers of human T-lymphotropic virus type I (HTLV-I). Informative markers to be studied include provirus load, HTLV-I antibody titer, anti-Tax protein, clonality of HTLV-I infected lymphocytes (viral markers), total immunoglobulin E (IgE), C-reactive protein (CRP), neopterin, soluble CD30, soluble interleukin-2 receptor (sIL2-R), EBV antibody profile (host immune markers), and proteomics. These markers were selected based on the measurability on the majority of specimens, availability of validated assays, relevance to the biology of T-cell malignancies, and has been used in a cross-sectional comparison of HTLV-I carriers and non-carriers from Japan and the Caribbean. We will utilize central laboratory and validated, standard assays for all specimens. The results, unlinked to personal identifiers, will be analyzed using generalized estimating equation. The findings will further our understanding of the etiology of ATL, and of differences in natural history of HTLV-I infection across geographic areas.

While pursuing the same theme of trying to identify host and viral markers associated with ATL, the unique aspect of this proposal is to pool ATL cases, an extremely rare malignancy, from multiple epidemiologic studies through international collaboration, in order to achieve adequate statistical power and to perform valid comparison of tumor characteristics across geographic areas.
No application will be made to the participants in this group. After the cesarean section, women will be evaluated for pain with VAS at 6-12-18 hours and half an hour after 6-12-18 hours, and their bowel sounds, flatulence and defecation will be recorded.
Induction chemotherapy plus concurrent chemoradiotherapy has the IIA evidence and the gemcitabine plus cisplatin (GP) regimen has the I evidence in the National Comprehensive Cancer Network (NCCN) guidelines for the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC). More and more evidence shows that immunotherapy combined with chemotherapy has a synergistic effect in treating tumors. GP chemotherapy combined with PD-1 inhibitor has achieved the initial effect in NPC. With the development of radiotherapeutic techniques and equipment as well as advances in treatment modalities, the 5-year overall survival of patients with non-disseminated NPC has exceeded 80%. But there are still about 20-30% of NPC patients who experienced recurrence or metastasis after radical chemoradiotherapy, especially locoregionally advanced patients. In order to improve their survival, we conduct this clinical trial to determine whether GP chemotherapy combined with PD-1 inhibitor as neoadjuvant therapy can improve the failure-free survival rate of locoregionally advanced NPC patients and provide new evidence for their neoadjuvant therapy of them.
The invention discloses a health-caring product for preventing and treating hyperglycemia and hyperlipidemia of a diabetic patient and a preparation method thereof. The preparation method includes steps of mixing, drying and crushing red yeast rice powder, a tartary buckwheat extract and a mulberry fruit juice. The preparation method is simple. By means of lovastatin in the red yeast rice powder, total flavonoids in the tartary buckwheat extract, 1-deoxynojirimycin in mulberry fruits and components such as various amino acids in a formula, blood glucose and blood fat can be inhibited or reduced. According to the formula, three raw materials are employed cooperatively so that a blood glucose reducing effect and a blood fat reducing effect can be improved. In addition, the mixture composed of the red yeast rice powder, the tartary buckwheat extract and the mulberry fruit juice provided in the invention can be used as a raw material. With addition of pharmaceutically acceptable auxiliary materials or components, the raw material can be prepared into tablets, capsules, granules, granular tea, or the like. The health-caring product has a huge medicinal and health-caring value.
BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is a standard therapy in patients with ischemic vascular diseases (IVD) including coronary artery, cerebrovascular and peripheral arterial diseases, although the optimal duration of this treatment is still debated. Previous meta-analyses reported conflicting results about the effects of long-term and short-term as well as non-DAPT use in various clinical settings. Herein, we conducted a comprehensive meta-analysis to assess the efficacy and safety of different durations of DAPT.
METHODS: We reviewed relevant articles and references from database, which were published prior to April 2023. Data from prospective studies were processed using RevMan5.0 software, provided by Cochrane Collaboration and transformed using relevant formulas. The inclusion criteria involved randomization to long-term versus short-term or no DAPT; the endpoints included at least one of total or cardiovascular (CV) mortalities, IVD recurrence, and bleeding.
RESULTS: A total of 34 randomized studies involving 141 455 patients were finally included. In comparison with no or short-term DAPT, long-term DAPT reduced MI and stroke, but did not reduce the total and CV mortalities. Meanwhile, bleeding events were increased, even though intracranial and fatal bleedings were not affected. Besides, the reduction of MI and stroke recurrence showed no statistical significance between long-term and short-term DAPT groups.
CONCLUSION: Long-term DAPT may not reduce the mortality of IVD besides increasing bleeding events, although reduced the incidences of MI and stroke early recurrence to a certain extent and did not increase the risk of fatal intracranial bleeding.
The present invention relates to novel testes related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "testicular antigens", and the use of such testicular antigens for detecting disorders of the testes, particularly the presence of testicular cancer and testicular cancer metastases. More specifically, isolated testicular associated nucleic acid molecules are provided encoding novel testes associated polypeptides. Novel testicular polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human testes associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the testes, including testicular cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
Aerobic exercise training of moderate intensity is recommended as safe and effective for all stable outpatients with chronic heart failure who are able to participate in improving physical conditioning. Emerging data suggest that high-intensity exercise training in select heart failure patients may achieve even greater improvement in functional capacity than moderate intensity training leading to a better quality of life. In the few studies to date, aerobic capacity, heart function is increased to a better extent in heart failure patients that undergo an eight-week high-intensity exercise program (32 exercise sessions) compared to the standard of care. The goal of this pilot study is to collect data on safety and efficacy of high-intensity interval training in stable heart failure patients to demonstrate better physiological and clinical outcomes with fewer long-term health care costs compared to the standard of care. Twenty participants with stable heart failure (age range = 40 to 65 years of age) will be randomized into two different groups: the standard of care group, in which subjects will exercise for 40 minutes at 40 to 60 % of heart rate reserve (HRR) for eight weeks (32 sessions); and the high-intensity interval training group, in which subjects will perform four sets of 4-minutes at \> 85% of HRR, with three minutes of active rest between intervals, for six weeks (32 sessions). The functional outcomes measured will be cardiac function (i.e. stroke volume, cardiac output, ejection fraction), pulmonary function (diffusing capacity, lung volumes, spirometry), exercise capacity (peak oxygen uptake) at rest and during exercise before and after eight weeks of exercise training (32 sessions). Adverse events related to each exercise training session (i.e. cardiac arrest, myocardial infarction during exercise, or within the first hour afterward) as well as arrhythmias will be recorded via Holter monitoring 24-hrs post-exercise. Quality of life will also be measured. The exercise training will be supervised at Grady Hospital. This novel approach has the chance to become impactful to these patients and will challenge the current negative perception of high-intensity exercise training in this patient population. The investigators anticipate this study will help reform the current exercise guidelines in these participants.
Prompt diagnosis and management of orbital entrapment fractures in the pediatric patient have been advocated. This retrospective study analyzed a cohort of orbital entrapment fractures in pediatric patients with regard to diagnostic pitfalls, treatment and outcomes in a Level I trauma center in Germany. Based on medical records and radiological imaging, patients under the age of 18 years who presented with orbital fractures during 2009-2021 were analyzed. Overall, 125 patients presented with orbital fractures, of whom 29 patients (23.2%) had orbital entrapment fractures. The majority of patients presented with monocle hematoma (n = 23), diplopia (n = 20), and/or restricted extraocular eye movement (n = 14). While all patients with orbital entrapment fractures underwent three-dimensional imaging, 10 radiological reports (34.5%) did not include findings on orbital entrapment fractures. All patients underwent surgical exploration in less than 24 h. In 12 patients, clinical symptoms such as diplopia and restricted ocular elevation were documented upon postoperative evaluation before discharge. Considering the significant proportion of orbital entrapment fractures that are not noted on radiological imaging, prompt clinical examination should be initiated in pediatric patients at risk for orbital fractures. Urgent surgical intervention should be recommended in entrapment fractures.
The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has room temperature stability advantages over known forms and dichloride salts. The novel crystalline form is characterized by having peaks at 22.9, 25.4, 25.8, 26 in the XRPD spectrum.6. Peaks and Raman shifts 943, 1173, 1527 and 1612 + -5 cm at 34.6 and 35.3 + -0.1 deg. 2 theta ‑1 . Crystalline forms of triethylenetetramine tetrachloride are useful for treating Wilson's disease. Also disclosed is a process for preparing a crystalline form of triethylenetetramine tetrachloride comprising adding an antisolvent to an aqueous solution of the compound.
SUTENT can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes was observed in <0.1% of patients.

Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with SUTENT.

Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing SUTENT [see Dosage and Administration (2.5), Drug Interactions (7.2)].
FIELD: biotechnology, microbiology. SUBSTANCE: strain Bifidobacterium breve 79-88 is isolated from healthy nurseling intestine content. Strain grows actively on nutrient media of different composition and accumulates industrial biomass for short, 16-24 h, time of culturing and at value of concentration of bacterial cells lg 8.6-8.95/1 ml. Strain ferments milk in 16-24 h of culturing and forms a clot with good taste and organoleptic properties. Strain exhibits specific activity producing acids and suppressing the growth of pathogenic and putrefactive microflora. Strain shows resistance to some antibacterial preparations. EFFECT: strain indicated above, valuable properties of strain. 2 tbl, 3 ex
A STSG donor site wound \>15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days.
Provided are a flexible, porous, dissolvable solid sheet article and a process for preparing the said sheet article. The process comprises: a) preparing a wet pre-mixture comprising a water-soluble polymer and a surfactant and having a viscosity of from 1,000 cps to 25,000 cps measured at 40? and 1 s -1; b) aerating said wet pre-mixture to form an aerated wet pre-mixture having a density of from 0.05 to 0.5 g/ml; c) forming said aerated wet pre-mixture into a sheet having opposing first and second sides; and d) drying said formed sheet for a drying time of from 1 minute to 60 minutes at a temperature from 70? to 200? along a heating direction that forms a temperature gradient decreasing from the first side to the second side of said formed sheet, wherein said heating direction is substantially opposite to the gravitational direction for more than half of the drying time. The said solid sheet article comprises a top region adjacent to said top surface, a bottom region adjacent to said bottom surface, and a middle region therebetween; wherein said top, middle and bottom regions have the same thickness, and each of said top, middle and bottom regions is characterized by an Average Pore Size; and wherein the ratio of Average Pore Size in said bottom region over that in said top region is from 0.6 to 1.5.
The invention relates to a camellia oil liposome preparation used for treating snoring and xerostomia, which belongs to the field of oil water emulsified mixture of natural vegetation. The liposome preparation is made by the base oil of functional camellia oil of the natural vegetation which is nutritious and has good wetting and moist effect on body, the mixture of aromatic pennyroyal of natural vegetation and the auxiliary seasoning oil of teal oil and medical de-ionized water. The soybean lecithin of natural vegetation oil is taken as emulsifier. The liposome emulsion of ultra-micro elaioleucite is formed by punchy homogeneous emulsification. The preparation is used for oral cavity and has good wetting quality and moisturizing ability. In addition, the preparation can deeply moisten the muscle of pharyngeal portion and die sticking and improve the blood stream of veins of the pharyngeal portion. During the function duration of eight hours, the preparation can keep the oral cavity wet, and promote breath, thus reducing or eliminating the snoring and the xerostomia. Clinical results show that the preparation can effectively improve all the indexes related to sleep test and has no untoward or adverse effects. So the camellia oil liposome preparation used for treating the snoring and the xerostomia is safe and reliable and can meet clinical requirements.
BACKGROUND: Inherited glycosylphosphatidylinositol (GPI) deficiency is an autosomal recessive disease and a set of syndromes caused by different genes involved in the biosynthesis of phosphatidylinositol characterized by severe cognitive disability, elevated serum alkaline phosphatase (ALP) levels, and distinct facial features. This report presents a patient with inherited GPI deficiency caused by a homozygous frameshift variant of PGAP3 due to uniparental isodisomy (UPiD) on chromosome 17.
METHOD: Clinical characteristics of the patient were collected. Microarray analysis followed by adaptive sampling sequencing targeting chromosome 17 was used for the identification of variants. Sanger sequencing was used to confirm the variant in the target region.
RESULTS: The patient was born at 38 weeks of gestation with a birthweight of 3893 g. He had a distinctive facial appearance with hypertelorism, wide nasal bridge, and cleft soft palate. Postnatal head magnetic resonance imaging revealed a Blake's pouch cyst. The serum ALP level was 940 IU/L at birth and increased to 1781 IU/L at 28 days of age. Microarray analysis revealed region of homozygosity in nearly the entire region of chromosome 17, leading to the diagnosis of UPiD. Adaptive sampling sequencing targeting chromosome 17 confirmed the homozygous variant NM_033419:c.778dupG (p.Val260Glyfs*14) in the PGAP3 gene, resulting in a diagnosis of inherited GPI deficiency.
CONCLUSION: This is the first report of inherited GPI deficiency caused by UPiD. Inherited GPI deficiency must be considered in patients with unexplained hyperphosphatasemia.
Epileptic patients who have been prescribed Keppra® (Levetiracetam) oral solution and who are between 1 and 11 months old. The patients will be followed as per current clinical practices for their condition. The choice of medical treatment, including the concomitant use of other antiepileptic drugs, is made independently by the physician in the regular course of practice and is not influenced by the study protocol.
<P>PROBLEM TO BE SOLVED: To provide an animal model for hypertrophic scar when screening medicines for hypertrophic scar.  <P>SOLUTION: The animal model for hypertrophic scar is produced by cutting a part of the skin of a rodent with a depth for cutting cutaneous muscle with a sufficient length to observe and breeding for 100 days. The rodent is preferably a rat and the rat is preferably a SD rat or a HWY hairless rat. The rat is applied to a test as a model after cut the cutaneous muscle and ensured that, monitoring the level of the hyperplasia with a replica of the treated position, the volume of the replica increases about 4 times of that of wound forming stage. The hypertrophic scar medicine can be evaluated by coating a specimen on a hypertrophic scar of a model animal for hypertrophic scar and observing decrease thereof.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
A color changing bar soap includes a small toy or figurine located inside a color changing layer such as a bicarbonate shell. The bicarbonate shell is housed within a body of soap. The bicarbonate surrounds and encapsulates the small toy. The soap fully surrounds and encapsulates the bicarbonate layer. The body of soap can be shaped like an egg or other various shapes to be determined, depending on the type of toy to be used with the soaps. In one embodiment, the egg-shaped soap is packaged onto a “nest-like” bail of hay or straw. This is placed inside a wooden or plastic crate for storage and use in a display.
In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program. Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.
PURPOSE: A composition with efficiency for treating and preventing obesity disease is provided to reduce body fat, triglyceride in blood, and blood cholesterol. CONSTITUTION: A medicine and health food composition for anti-obesity contains 40-80 weight% of Saururus chinensis Baill extract, 10-50 weight% of Poria cocos (Schw.) Wolf extract and 10-50 weight% of Atractylodes ovata (Thunb.) DC. extract. A medicine and health food composition for preventing or treating obesity or cardiovascular diseases contains the composition for anti-obesity as an active ingredient.
The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.   The most suitable drawing: FIG. 1.
The three main treatments available for intermittent claudication are:

  * Exercise. Your doctor may advise an exercise program. 
  * Medication. Your doctor may prescribe a medication such as cilostazol. (See Who should not take cilostazol?) 
  * Surgery. Your doctor may recommend a surgical procedure to bypass the blocked segment of the artery. Another procedure is called a percutaneous transluminal angioplasty. In this procedure, a catheter (a flexible tube) is inserted into the artery to reduce the blockage and improve blood flow.
OBJECTIVE: Acute heart failure (AHF) is one of the most common conditions presenting to the ED and patients often require hospitalisation. Emerging evidence suggests early diagnosis and administration of diuretics are associated with improved patient outcomes. Currently, there is limited literature on the management of AHF in the Australian ED context.
METHODS: A retrospective review of consecutive AHF presentations to the ED in a metropolitan hospital. Patient demographics, clinical status and management were assessed including timeliness of diuretics administration and association with outcomes including ED length of stay (LOS) and inpatient mortality using linear regression.
RESULTS: One hundred and ninety-one presentations (median age 81 years, 50.8% male) were identified. Common cardiovascular comorbidities were prevalent. Fifty-four patients (28.3%) had ≥1 clinical high-risk feature at presentation. The median time from presentation to furosemide administration was 187 min (interquartile range 97-279 min); only 35 patients received diuretics within 60 min of presentation. Early diuretics was associated with shorter ED LOS (246 min vs 275 min, P = 0.03) and a lower but non-significant inpatient mortality (4.9% vs 6.3%, P = 0.21) and a non-significant increased rate of discharge home from ED (8.6% vs 4.7%, P = 0.15). The likelihood of discharge home was significantly more pronounced in patients receiving early diuretics without clinical high-risk features (16.7% vs 4.3%, P = 0.028).
CONCLUSION: Despite symptoms and signs being well recognised at presentation, time to diuretics was relatively long. Early diuretics administration was associated with improved patient outcomes, particularly in clinically more stable patients. Due to the limitations of the study design, results should be interpreted with caution and warrant further research to identify factors that delay timely administration of diuretics.
This group receives a Chinese calligraphy training program of 16 sessions over 8 weeks in a class of 8-12 participants. Each session is 1.5 hours.